乙-CoA合成酶4调节乳腺癌细胞中的线粒体功能
Yanina Benzo1,2, Jesica G Prada2, Melina A Dattilo1,2
1Universidad de Buenos Aires, Facultad de Medicina, Departamento de Bioquímica Humana, Buenos Aires, Argentina.
Heliyon
|May 17, 2024
概括
在乳腺癌中,乙烯基-CoA合成酶4 (ACSL4) 调节线粒体功能和新陈代谢. 过度表达ACSL4可以促进呼吸活动和糖分分解功能,而它的抑制会降低这些效应,影响癌症的进展.
科学领域:
- 细胞生物学 细胞生物学
- 癌症新陈代谢 癌症新陈代谢
- 线粒体动力学的动力学
背景情况:
- 线粒体对于癌细胞的生存和增殖至关重要.
- 改变的线粒体生物能量是癌症的标志.
- 乙-A合成酶4 (ACSL4) 与侵袭性癌症表型和脂质代谢有关.
研究的目的:
- 研究ACSL4在调节乳腺癌细胞中的线粒体功能和新陈代谢中的作用.
- 为了确定ACSL4如何影响关键的线粒体蛋白和呼吸系统参数.
主要方法:
- 在MCF-7乳腺癌细胞中过度表达ACSL4.
- 在MDA-MB-231乳腺癌细胞中,ACSL4的破坏.
- 分析线粒体调节蛋白 (NRF-1,VDAC1,复合III),氧消耗率 (OCR),备用呼吸能力 (SRC),甘油功能和线粒体质量.
主要成果:
- ACSL4过度表达增加了NRF-1,VDAC1和复合III的mRNA和蛋白质水平.
- ACSL4过度表达导致高氧消耗率 (OCR) 和备用呼吸能力 (SRC).
- ACSL4敲击降低了OCR和SRC; ACSL4调节了线粒体质量和糖解功能.
结论:
- 在乳腺癌中,ACSL4在调节线粒体功能和新陈代谢方面发挥着重要作用.
- ACSL4影响关键的线粒体蛋白质,生物能量参数和细胞代谢.
- 这些发现扩大了对ACSL4参与乳腺癌进展的理解.
相关概念视频
Electron Transport Chain: Complex I and II
13.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.1K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Regulation of Metabolism
9.4K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.4K
ATP Synthase: Mechanism
14.5K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
14.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


